newsfilter
← Latest News
Business Wire·

Arcturus Therapeutics Provides Interim Phase 2 Data for Cystic Fibrosis (CF) Program

ARCT-032 generally safe and well tolerated Meaningful trends of clinical activity observed via high resolution CT scans After only 28 days of treatment with ARCT-032 (10 mg), 4 out of 6 Class I CF participants